MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELLS AND USES THEREOF TO TREAT AUTOIMMUNE DISORDERS

1 . A multifunctional molecule, comprising:

(i) a first antigen binding domain that binds to, e.g., selectively binds to, T cell receptor variable beta (TCRBV), e.g., a TCRBV antigen,

and

(ii) one, two, or all of:

(a) an immune cell engager chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager;

(b) a cytokine molecule or cytokine inhibitor molecule; and

(c) a death receptor signal engager.

2 . A multifunctional molecule, comprising:

(i) a first antigen binding domain that binds to, e.g., selectively binds to, T cell receptor variable beta (TCRBV), e.g., a TCRBV antigen, and

(ii) an NK cell engager, e.g., an anti-NKp30, anti-NKp46, anti-NKG2D, or anti-CD16 antibody molecule.

3 . The multifunctional molecule of claim 2 , wherein the NK cell engager comprises an anti-NKp30 antibody molecule.

4 . The multifunctional molecule of claim 2 , wherein the NK cell engager comprises an anti-NKp46 antibody molecule.

5 . A multifunctional molecule, comprising:

(i) a first antigen binding domain that binds to, e.g., selectively binds to, T cell receptor variable beta (TCRBV), e.g., a TCRBV antigen, and

(ii) a death receptor signal engager.

6 . A multifunctional molecule, comprising:

(i) a first antigen binding domain that binds to, e.g., selectively binds to, T cell receptor variable beta (TCRBV), e.g., a TCRBV antigen, and

(ii) a cytokine inhibitor molecule.

7 . A nucleic acid molecule encoding the multifunctional molecule of any one of claims 1 - 6 .

8 . A vector, e.g., an expression vector, comprising the nucleic acid molecules of claim 7 .

9 . A host cell comprising the nucleic acid molecule of claim 7 or the vector of claim 8 .

10 . A method of making, e.g., producing, the multifunctional molecule or antibody molecule of any one of claims 1 - 6 , comprising culturing the host cell of claim 9 , under suitable conditions, e.g., conditions suitable for gene expression and/or homo- or heterodimerization.

11 . A pharmaceutical composition comprising the multifunctional molecule of any one of claims 1 - 6 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

12 . A method of treating a TCR bias, comprising administering to a subject in need thereof the multifunctional molecule of any one of claims 1 - 6 , wherein the multifunctional molecule is administered in an amount effective to treat the TCR bias.

13 . A method of treating an autoimmune disease (e.g., an autoimmune disease associated with a TCR bias), comprising administering to a subject in need thereof the multifunctional molecule of any one of claims 1 - 6 , wherein the multifunctional molecule is administered in an amount effective to treat the autoimmune disease.

14 . A method of treating a TCR bias, comprising:

responsive to determining that a subject has a TCR bias, administering to a subject in need thereof the multifunctional molecule of any one of claims 1 - 6 , wherein the multifunctional molecule is administered in an amount effective to treat the TCR bias.

15 . A method of treating an autoimmune disease (e.g., an autoimmune disease associated with a TCR bias), comprising:

responsive to determining that a subject has an autoimmune disease (e.g., an autoimmune disease associated with a TCR bias), administering to a subject in need thereof the multifunctional molecule of any one of claims 1 - 6 , wherein the multifunctional molecule is administered in an amount effective to treat the autoimmune disease (e.g., an autoimmune disease associated with a TCR bias).

16 . A method of identifying a subject in need of treatment for cancer using a multifunctional molecule of any of claims 1 - 6 , comprising determining (e.g., directly determining or indirectly determining, e.g., obtaining information regarding) whether a subject has a TCR bias (e.g., a biased TCRBV clonotype) and/or an autoimmune disease associated with said bias, wherein:

responsive to determining that the subject has a TCR bias (e.g., a biased TCRBV clonotype) and/or an autoimmune disease associated with said bias, identifying the subject as a candidate for treatment using a multifunctional molecule comprising an antigen binding domain that binds to the TCRBV antigen, and optionally not as a candidate for treatment using a multifunctional molecule comprising an antigen binding domain that does not bind to the TCRBV antigen (e.g., that binds to a different TCRBV antigen).

17 . A method of evaluating a subject in need of treatment for a TCR bias (e.g., a biased TCRBV clonotype) and/or an autoimmune disease associated with said bias, comprising determining (e.g., directly determining or indirectly determining, e.g., obtaining information regarding) whether a subject has a TCR bias.

18 . A method of treating an autoimmune disease (e.g., an autoimmune disease associated with a TCR bias), in a subject in need thereof, comprising administering to said subject an effective amount, e.g., a therapeutically effective amount, of an antibody molecule which binds (e.g., specifically binds) to a T cell receptor beta variable region (TCRβV) (“anti-TCRβV antibody molecule”), thereby treating the disorder.

19 . A method of depleting a population of T cells in a subject having an autoimmune disorder (e.g., an autoimmune disease associated with a TCR bias), comprising, contacting the T cell population with an effective amount of an antibody molecule which binds (e.g., specifically binds) to a T cell receptor beta variable region (TCRβV) (“anti-TCRβV antibody molecule”).

20 . The method of claim 19 , wherein the contacting occurs in vivo or in vitro.

21 . The method of any one of claims 18 - 20 , wherein the anti-TCRβV antibody molecule:

(i) is not an antibody molecule disclosed in U.S. Pat. No. 5,861,155;

(ii) binds to TCRβ V12 with an affinity and/or binding specificity that is less than (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10-fold) the affinity and/or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in U.S. Pat. No. 5,861,155;

(iii) binds to TCRβ V12 with an affinity and/or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10-fold) the affinity and/or binding specificity of the 16G8 murine antibody or a humanized version thereof as described in U.S. Pat. No. 5,861,155;

(iii) binds to TCRβ V5-5*01 or TCRβ V5-1*Ol with an affinity and/or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10-fold) the affinity and/or binding specificity of the TM23 murine antibody or a humanized version thereof as described in U.S. Pat. No. 5,861,155 or

(iv) binds to TCRβ V5-5*01 or TCRβ V5-1*01 with an affinity and/or binding specificity that is greater than (e.g., greater than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or about 2-, 5-, or 10-fold) the affinity and/or binding specificity of the TM23 murine antibody or a humanized version thereof as described in U.S. Pat. No. 5,861,155.

22 . The method of any one of claims 18 - 21 , wherein the anti-TCRβV antibody molecule comprises an Fc region, e.g., an Fc region having effector function, e.g., antibody dependent cell-mediated cytotoxicity (ADCC), Antibody-dependent cellular phagocytosis (ADCP) and/or complement dependent cytotoxicity (CDC).

23 . The method of any claim 22 , wherein the anti-TCRβV antibody molecule comprises an Fc region with enhanced effector function, e.g., as compared to a wildtype Fc region.

24 . The method of any one of claims 18 - 23 , wherein the anti-TCRβV antibody molecule comprises a human IgG1 region or a human IgG4 region.